SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RDHL

RedHill Biopharma Ltd. (NASDAQ:RDHL)

IL · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$0.28-$0.04 (-13.08%)
 
Market cap
$883K
Insider Score
Health Score
Analyst consensus
Listed since
Jan 7, 2013
Market Cap$883.14K-72.7%
Revenue (ttm)$0+16.0%
Net Income-$6.10M+33.3%
EPS$0.00+85.0%
Shares Out3.14M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,254
Open$0.31
Previous Close$0.32
Day's Range$0.28 - $0.34
52-Week Range$0.28 - $1.60
Beta4.87
AnalystsBuy
Price Targetn/a
Earnings DateMar 18, 2027
-13.39% (1D)
No price history available.

About RDHL

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

Address
21 Ha’arba’a Street, Tel Aviv, TA, 6473921, IL
Market Cap
1 million
Employees
13
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$4.42K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From RDHL’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-13.08%
5 Days
-25.07%
1 Month
-33.43%
6 Months
-71.32%
1 Year
-72.72%

$RDHL stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RDHL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RDHL's directors and management

Net Shares Purchased by Insiders−20M−10M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RDHL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RDHL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RDHL from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from RDHL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
0
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
3
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.